Possible advantage of imiquimod and diphenylcyclopropenone combined treatment versus diphenylcyclopropenone alone: An observational study of nonresponder patients with alopecia areata

• DOI: 10.1111/ajd.12478
• Publication Date: 2016-04-18T02:43:09Z
• Authors: Tomasz Wasyłyszyn; Katarzyna Borowska
• Keywords: Imiquimod

Abstract The topical contact sensitiser diphenylcyclopropenone ( DCP ) remains one of the most effective treatment modalities for alopecia areata AA ). However, some patients (nonresponders) do not respond to this because they have an allergic reaction . aim study was investigate potential role imiquimod in inducing nonresponders. In all, 20 nonresponders were recruited from a group ‐treated patients. Of these patients, 10 treated with and alone. A significantly better therapeutic outcome measured plus than mechanism may involve interleukin‐12, as previously suggested animal model. These findings suggest that improve prognosis nonresponder